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Abstract
Background: Antibiotics (AB) are an important tool to tackle infectious disease in pig farms; however some
research indicates that their frequent mis/over-use may contribute to the development of antibiotic resistance and
the WHO has declared that this issue should be addressed. Little is known about the long term consequences of
withdrawing prophylactic AB from pig feed; hence we aimed to assess its effects on performance and health of
pigs from weaning to slaughter.
Six batches of 140 pigs each were monitored on a commercial farm through the weaner and finisher stages to
slaughter. In-feed antibiotics were not added to the feed for half of the pigs (NOI) and were added in the other half
(ABI) within each batch for the whole weaner stage. Individual pigs in both treatments were treated with parenteral
administrations if and when detected as ill or lame. Productive performance, parenteral treatments and mortality
were recorded on farm and the presence of respiratory disease was recorded at slaughter. Pen was considered the
experimental unit.
Results: ABI pigs showed higher growth (P = 0.018) and feed intake (P = 0.048) than NOI pigs in the first weaner
stage but feed efficiency was not affected (NOI = 1.48 vs. ABI = 1.52). Despite an initial reduction in performance,
NOI pigs had similar performance in finisher stage (ADG: NOI = 865.4 vs. ABI = 882.2) and minimal effects on health
compared to ABI pigs. No difference between treatments was found at the abattoir for the percentage of pigs
affected by pneumonia, pleurisy, pleuropneumonia and abscesses (P > 0.05). Mortality rate was not affected by
treatment during the weaner stage (P = 0.806) although it tended to be slightly higher in NOI than ABI pigs during
the finisher stage (P = 0.099). Parenteral treatments were more frequent in NOI pigs during the weaner stage
(P < 0.001) while no difference was recorded during the finisher stage (P = 0.406).
Conclusions: These data suggest that the removal of prophylactic in-feed antibiotics is possible with only minor
reductions in productive performance and health which can be addressed by improved husbandry and use of
parenteral antibiotics.
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Background
Antibiotic (AB) usage in intensive livestock systems has
been associated with antibiotic resistance (ABR) in some
studies and the WHO (World Health Organization) has de-
clared it a risk for both human and animal health [1]. The
ban of AB as growth promoters was applied by the
European Union in 2006 [2] and was important in reducing
AB use. Ten years later, prophylactic AB are still used at
high levels in many countries to sustain animal health and
welfare [3, 4]. In order to promote more responsible use of
AB, use should be assessed regularly, only allowed if strictly
needed and alternative solutions should always be in place
[5]. Such measures would help to reduce the selection
pressure which contributes to the spread of ABR [5, 6].
The pig industry uses more medication (mg of active
ingredient / population correction unit) than other live-
stock sectors, especially during the weaning period [7]
when pigs face several challenges and stressors including
changes in diet, separation from the sow and re-mixing.
These changes stress the animals and compromise their
immune system [8], making them more susceptible to
infectious agents [9, 10]. The practice of prophylactic
AB administered via the feed is an easy way of avoiding
or reducing the risk of disease in weaned pigs. However,
as such use is associated with a high likelihood of
broad-spectrum usage or misuse [4, 11] it poses a threat
for public health [12, 13]. The ban of in-feed AB usage
proposed by the EU [14] includes provision for the re-
moval of prophylactic in-feed AB use and the adoption
of alternative strategies such as improved vaccinations
or new management procedures [15–18]. Parenteral
administration of AB would still be allowed, ensuring a
more limited and targeted approach.
There are some published data suggesting that with-
drawal of prophylactic AB is not necessarily associated
with negative effects on production [19]. However,
research is lacking on the long term consequences of
withdrawing prophylactic AB on performance and health
of pigs in commercial farms considering the whole pro-
duction cycle. This information would be useful for vet-
erinarians and policy makers in order to identify the
most suitable practices to reduce the use of AB. Thus,
the objective of this study was to assess the effect of
removing prophylactic in-feed AB from the diet of
weaner pigs on a commercial farm, allowing parenteral
treatments as needed, on pig performance and health
throughout the whole production cycle.
Results
On farm measurements
Production data, mortality and parenteral administration of
antibiotics
ABI pigs had higher ADG (P = 0.018) and ADFI (P =
0.048) than NOI pigs during the first weaner stage which
led to 2 kg non-significant difference in final body weight
between treatments at the end of the second weaner (P
= 0.218) and finisher (P = 0.483; Table 1) stages. There
was no difference in ADG, ADFI and FCR between ABI
and NOI pigs during the finisher stage (P > 0.05, Table 1).
Mortality rate tended to be higher in NOI pigs than ABI
pigs during the finisher stage (P = 0.099) but was not
affected by treatment during the entire weaner stage (P =
0.806; Table 2). There was a difference between treatments
in the total amount of parenteral administration of AB
(sum of doses administered when pigs were detected to be
lame and/or systemically ill) during the entire weaner
stage, with a total of 25% vs. 13.8% of pigs treated for NOI
and ABI pigs, respectively (P < 0.001). No difference
between treatments was recorded during the finisher stage
for total parenteral treatments (P = 0.406; Table 2). Data
were also analysed according to the reason for treatment
(i.e. lameness or systemic illness, Table 2). Parenteral treat-
ments for lameness did not differ between treatments for
weaner pigs but differed for finisher pigs (NOI = 18.7% vs.
ABI = 13.1%, P = 0.036). Parenteral treatments for systemic
illness differed for weaner (NOI = 23.6% vs. ABI = 12.4%,
P < 0.001) but not for finisher pigs (P = 0.314).
Initial weaning and finishing BW were negatively
associated with mortality rate and percentage of paren-
teral administrations of AB recorded during both stages
(Table 3). Lighter weaner pigs were at greater risk of
death (P = 0.056) and of being injected (P = 0.036) and
lighter finishing pigs were at higher risk of being injected
(P < 0.010; Table 3).
Tail lesions
There was no difference in the percentage of pigs af-
fected by tail lesions during the first (P = 0.168), second
(P = 0.162) and finisher (P = 0.257) stages between ABI
and NOI pigs (Table 4). At weaning, no association was
detected between BW at the end of this stage and the
percentage of pigs affected by tail lesions (P = 0.297),
while at finishing final BW was negatively associated
with percentage of pigs affected by tail lesions, with
lighter pigs being at greater risk of having tail lesions
(P = 0.018).
Slaughterhouse measurements
Less than 1% of heart, liver and lung condemnations
were recorded at slaughter, therefore these data were not
analysed. There were no differences in EP (P = 0.365)
and pleurisy (P = 0.460) scores between ABI and NOI
pigs (Table 5). Moreover, no difference between treat-
ments was found for the percentage of pigs affected
by EP (P = 0.945), pleurisy (P = 0.277), APP (P = 0.300)
or abscesses (P = 0.142). The means and the corre-
sponding standard error for each treatment are
presented in Table 5.
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Discussion
The objective of this study was to assess the effect of
removing prophylactic in-feed AB, but allowing paren-
teral treatments, on pig health and performance from
weaning until slaughter. Although there is considerable
variation in management and housing practices between
Irish farms, the farm selected for this study was consid-
ered representative of the general situation in this coun-
try as it was a medium sized farm where the use of
in-feed AB had become regular practice as an easy
option to control background diseases.
Farmers benefit from the continuous use of in-feed
prophylactic AB as it improves performance in a similar
manner to the use of AB for growth promotion [11, 20].
Results from this study revealed that the use of AB at
the weaner stage had indeed clear benefits for perform-
ance. Many studies on the use of in-feed AB in the
weaning period have concluded that it is necessary to
maintain performance as reviewed by Thacker [21].
However, this study showed that when the trial period
was extended to the finisher stage where AB were not
provided in pig feed, the differences in performance
were not significant despite the fact that pigs with AB in
their feed (ABI pigs) reached slaughter 2 kg heavier than
pigs without (NOI pigs). The final heavier weight of ABI
pigs was the result of higher ADG and ADFI during the
first weaner stage. However, no difference in FCR was
found between treatments showing that NOI pigs were
as efficient as ABI pigs. Thus, the possible benefit of the
extra sale weight is not so important economically as the
amount of feed used is also less. Additionally, with-
drawal of AB may also result in benefits for both
consumers and farmers given the reduction in the
amount of AB used.
During the weaner stage, NOI pigs had received
double the parenteral treatments than ABI pigs. This
difference might have been even more pronounced if the
2 groups of pigs had not shared the same room and air
space; separation of the 2 groups might have reduced
the infection pressure and the need for parenteral antibi-
otics in the ABI pigs. Nevertheless, the use of parenteral
AB instead of in-feed AB still represents a very import-
ant reduction in the total use of AB per pig and probably
allows for more accurate dosing of the AB, thus contrib-
uting less to AB resistance. On the other hand, the
number of parenteral treatments in finisher pigs did not
differ between treatments, showing that although the
NOI pigs showed more clinical signs of illness during
the weaning stage, this did not result in further conse-
quences for the health of pigs during the finishing stage.
There was also no difference between treatments in
health indicators collected at the abattoir (EP, abscess,
APP and pleurisy) or on tail lesions collected prior to
slaughter. This also supports the hypothesis that with-
drawal of in-feed medication did not compromise pig
health which is in accordance with the results of other
studies [15, 22, 23] where removal of in-feed AB did not
result in health problems. However, looking at the differ-
ent reasons for parenteral treatments, during the weaner
stage the difference between groups was mainly because
of systemic illness, whereas at finishing, it was because
of lameness affecting NOI pigs. This difference may
suggest some carryover effect of disease during the
weaning stage. Infectious arthritis, often related to
streptococcal infection, is a common cause of lameness
in pigs [24, 25]. In-feed AB may provide protection
against subclinical infections, sequestered in areas such
as joints and that reappear later in the production cycle.
However, given the multiple possible causes of lameness
Table 1 Production data. Average daily gain (ADG), average daily feed intake (ADFI), feed conversion ratio (FCR) and body weight
(BW) for pigs provided with in-feed antibiotics (ABI) and for pigs with no in-feed antibiotics (NOI)
First weaner stagea Second weaner stagea Finisher stage
Variables NOI ABI P-value NOI ABI P-value NOI ABI P-value
ADG g 402.2 ± 18.20 435.6 ± 13.03 0.018 711.0 ± 32.31 743.7 ± 42.58 0.774 865.4 ± 29.29 882.2 ± 29.29 0.893
ADFI g 584.6 ± 39.88 646.5 ± 28.83 0.048 1380.9 ± 29.29 1440.2 ± 60.09 0.589 1811.1 ± 31.09 1818.8 ± 36.92 0.984
FCR 1.48 ± 0.034 1.52 ± 0.032 0.483 1.95 ± 0.054 1.95 ± 0.045 0.944 2.10 ± 0.040 2.07 ± 0.038 0.853
BW Kg 21.9 ± 0.85 23.0 ± 0.70 0.032 41.4 ± 1.36 43.3 ± 1.40 0.218 99.4 ± 1.55 101.4 ± 1.91 0.483
Data are presented as means ± SEM (standard error of the mean)
a First and second weaner stages data has already been published in Diana et al. (2017) [11]
Table 2 Mortality rate and parenteral administration of
antibiotics for pigs provided with in-feed antibiotics (ABI) and
for pigs without in-feed antibiotics (NOI)
Weaner stage Finisher stage
Variables NOI ABI P-value NOI ABI P-value
Mortality rate%a 2.14 1.9 0.806 3.13 1.33 0.099
Injections tot %b 25 13.8 < 0.001 34.1 31.2 0.406
Injections lame%1 1.4 1.4 0.999 18.7 13.1 0.036
Injections sick%2 23.6 12.4 < 0.001 15.3 18.1 0.314
a Percentage of pigs that died during weaner and finisher stages
b Percentage of the animals treated based on the total number of parenteral
administrations (in doses) recorded when pigs were considered systemically ill
and lame, lame only1 and systemically ill only2 during weaner and
finisher stages
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[26] further studies should be carried out to elucidate
the reasons for the increase in lameness observed in pigs
without AB in their diet. The higher mortality rate found
at the finishing stage also supports the view that there
may be a carryover effect from the weaner stage as no
difference in mortality was detected during the weaner
stages.
Finally, the relationships found between bodyweight,
the percentage of parenteral treatments and mortality
during both weaner and finisher stages reflect the strong
link between weight of pigs at weaning and their suscep-
tibility to disease. Other studies showed how lighter pigs
had higher level of disease after weaning [27]. This
suggests that body weight at weaning could be used as
an early tool to monitor pigs that are considered at risk
of disease later in life.
Before this study started, basic management practices
such as stocking density, environmental control and
enrichment were reviewed to make sure that removal of
AB would not expose pigs to any unnecessary risks. In-
deed, poor management conditions such as low levels of
hygiene, unfavourable temperature or high stocking
densities may facilitate the spread of pathogens [28].
Under such a scenario, in-feed AB show their greatest
impact because they become an effective tool to control
disease [29, 30]. Therefore, some simple adjustments
were made but there was no financial investment to
improve the housing or management of the pigs. Thus
removal of in-feed prophylactic AB was possible without
major risks for general pig health. Numerical differences
in productive performance and mortality may be sug-
gestive of some consequences of removing in-feed AB.
However, in depth analysis of biosecurity, management
and husbandry practices [31, 32] could provide sufficient
information to allow correction of failures in these areas
and prevention of such consequences. Additionally,
injection of AB in clinically affected pigs may have con-
tributed to the absence of health issues found in NOI
pigs given that double the number of injections was ad-
ministered during the weaner stages. It is also likely that
greater vigilance on the part of the farm staff taking care
of NOI pigs ensured that animals with early signs of
clinical illness were promptly treated. This might also be
expected in other farms where in-feed AB are removed.
The importance of developing new strategies and pro-
viding proper AB stewardship is underpinned by the
possible contribution of AB use to the development of
AB resistance [1]. Over/misuse may have detrimental
implications for the length of treatment applied and for
efficacy of the AB treatment. There was prolonged
non-specific prophylactic treatment of weaner pigs on
the study farm. Unfortunately, given the high use of
in-feed AB in weaner pigs in some EU countries [7], it is
Table 3 Associations between initial body weight (BW) and the
percentage of parenteral administrations of antibiotics and
mortality rate and between final body weight and the
percentage of pigs per pen affected by tail lesions across all
pigs included in the study regardless of treatment
Variables Initial BW1 P-value Final BW2 P-value
R* R*
Weaner stage
Parenteral administrations
%a
- 0.61 0.036
Mortality rate %b - 0.56 0.056
Tail lesions %c 0.33 0.297
Finisher stage
Parenteral administrations
%a
- 0.54 0.002
Mortality rate %b - 0.17 0.384
Tail lesions %c - 0.52 0.018
*Correlation coefficients
1Body weight (kg) of pigs when moving to weaner and finisher stages
2Body weight (kg) of pigs at the end of the weaner and finisher stages
aPercentage of the animals treated based on the number of parenteral
administrations (in doses) recorded when pigs were considered sick and/or
lame during weaner and finisher stages
bPercentage of pigs that died during weaner and finisher stages
cPercentage of pigs per pen affected by tail lesions during weaner and
finisher stages
Table 4 Average percentage of pigs per pen affected by tail
lesions for pigs provided with in-feed antibiotics (ABI) and for
pigs with no in-feed antibiotics (NOI) during three time points
of the production system
Production stages NOI ABI P-value
First weaner % 5.9 ± 1.69 11.1 ± 3.47 0.215
Second weaner % 2.9 ± 1.34 8.2 ± 3.11 0.152
Finisher % 22.4 ± 7.35 13.6 ± 4.80 0.312
Data are presented as means ± SEM
Table 5 Results of EP (enzootic pneumonia) and pleurisy score and
percentage of pigs with EP, pleurisy, lesions of APP (Actinobacillus
pleuropneumoniae) and abscess recorded at slaughter for pigs with
in-feed antibiotics (ABI) and without in-feed antibiotics (NOI)
Variables NOI ABI P-value
EP score1,a 3.8 ± 6.75 5.0 ± 9.40 0.365
Pleurisy score1,b 0.5 ± 0.82 0.6 ± 0.83 0.460
EP % 40.8 41.3 0.945
Pleurisy % 33.7 41.3 0.277
APP % c 0 1.1 0.300
Abscess % c 0 2.2 0.142
1Data are presented as mean ± SE
%= percentage of pigs affected by EP (enzootic pneumonia), pleurisy, APP
(Actinobacillus Pleuropneumonia) and abscess
aScored according to the British Pig Executive, British Pig Health
Scheme (2016)
bScored using the Slaughterhouse Pleurisy Evaluation System (SPES; Dottori et
al., 2007) from 0 = no lesions to 4 = severely extended lesions (at least 1/3 of
both diaphragmatic lobes) and/or acute (exudation and abundant
granulation tissue)
cRecorded as present or absent
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likely that this farm is typical of many others both in
Ireland and elsewhere. The type of withdrawal applied in
this study resulted in a 97% reduction in overall AB use
as measured in doses withdrawn from NOI pigs. This
level of reduction may represent an advantage for both
the finances of farmers and for public/animal health
given the supposed contribution of AB use to the devel-
opment of antibiotic resistance. However, if we consider
the 2 kg lower weight at slaughter in NOI pigs, the
saving on AB would not be enough to compensate this
reduction in income. This is an important commercial
issue to be considered when implementing legislation on
this area.
Conclusions
Overall, withdrawal of prophylactic in-feed AB did not
result in major detrimental problems for performance
and health and welfare of pigs. Untreated pigs were as
efficient as pigs fed with AB although there were numer-
ical reductions in production performance and a ten-
dency towards higher mortality in the finisher stage.
These results indicate that the removal of prophylactic
in-feed AB, while still allowing the use of parenteral AB,
is possible but will need some extra measures to be
implemented to avoid loss of profit and impaired pig
welfare.
Methods
Farm and animals
The study was carried out on a 300-sow farrow-to-finish
commercial farm with a history of regular use of in-feed
AB and included 6 weekly batches of Large White ×
Landrace crossbred pigs (840 pigs in total). The farmer
expressed his willingness to cooperate with the intensive
data collection required during the period of study
which took place between September 2014 and February
2015. In order to comply with Council Directive 2008/
120/EC, some changes in management such as an im-
proved programme of environmental enrichment and a
reduction in stocking density were introduced at the
farm before the start of the study [11]. As per regular
practice, piglets were first weaned at 28 ± 2 days of age
and relocated to the first stage weaner accommodation
where they spent 5 weeks. Thereafter pigs were moved
to the second stage weaner accommodation for a further
4 weeks and finally to the finishing stage where the
animals spent 8 to 11 weeks depending on the time they
required to reach slaughter weight (approximately 110
kg). The farm had a clinical history of disease including
episodes of meningitis and diarrhoea in the first stage
weaner pigs and pleuropneumonia outbreaks both in the
second stage weaners and finishers. Pigs were positive
for porcine reproductive and respiratory syndrome virus
(PRRSv), Actinobacillus pleuropneumoniae, Mycoplasma
hyopneumoniae and swine influenza virus. In-feed
prophylactic medication with sulfadiazine-trimethoprim
(TMS) and therapeutic levels of ZnO (3000 ppm for 2
weeks) were used to address these clinical problems.
Weaner pigs were housed in rooms with four pens of
35 pigs each for the first stage and in rooms with eight
pens of 17 pigs each for the second stage. Finisher pigs
were housed in Trowbridge style pens (each pen is an
independent room) of 21 to 23 pigs. Rooms for each
stage had the same design and environmental control.
Density was a minimum of 0.30 m2 per pig in the first
stage weaner and a minimum of 0.40 m2 per pig in the
second stage weaner. In the finisher stage density was a
minimum of 0.65 m2 per pig. Pigs were housed on fully
slatted floors, plastic for weaners with solid plastic panel
pen divisions, and concrete for finisher pigs. Weaning
facilities had an automatic temperature control system
with fans in the ceiling and temperature was maintained
at the recommended average of 26 °C for the first and
22.5 °C for the second stage [33]. The room was artifi-
cially illuminated from 0800 till 1700 h. The finisher
facilities were naturally ventilated and lit with natural
daylight. All pens had at least one nipple drinker with ad
libitum water provided.
Pigs were weaned onto a commercial starter diet +
electrolyte solution for a week and then moved to a
weaner diet followed by a finisher diet, both of which
were home milled. The weaner diet included corn (30%),
barley (24.5%), soya bean meal 48% (23.5%), wheat
(13.6%), lactofeed (Volac, Ireland; 2.5%) and soy oil
(2.5%) (CP = 19.0%, DE = 14.4 MJ/kg, SID Lys = 1.15).
The finisher diet included wheat (46%), barley (30%),
soya bean meal 48% (18%), soy hulls (2%) and soy oil
(1%) (CP = 16.3%, DE = 14.2 MJ/kg, SID Lys = 0.91). Pigs
had ad libitum access to feed provided by a SPOTMIX
liquid feeding system (Schauer Agrotronic GmbH,
Prambachkirchen, Austria) and pens were furnished with
environmental enrichment. This study was approved by
the Teagasc Animal Ethics Committee (approval no.
TAEC 40/2013) and the farm complied with Council
Directive 2008/120/EC.
Experimental design and treatment
Six weekly batches of 140 pigs were individually identi-
fied with an ear-tag and weighed at weaning (840 pigs in
total, 9.2 ± 0.6 kg). During both weaning stages (for a
total of nine weeks/five days a week), pigs received a diet
where the in-feed AB (sulfadiazine-trimethoprim, 14.4
mg/kg BW/d) was randomly added to the diet (ABI) or
not (NOI). In-feed AB were not administrated during
the finisher stage, however pigs belonging to the same
treatment (i.e. NOI or ABI) pens were kept together
when moved to this production stage. This medication
pattern was prescribed by the practising veterinarian 6
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months before the study started in an empirical ap-
proach as per usual practice. Pigs were otherwise man-
aged as per usual practice on the farm. Hence, it is
important to highlight that pen composition changed
between each stage according to regular farm manage-
ment practices but the two populations of study pigs
were kept separate throughout the production cycle.
Due to these changes, the final number of pen replicates
per treatment for the 6 batches was 12 for the first stage
weaner, 24 for the second stage weaner and 18 pens for
the finisher stage. During both weaning and finisher
stages, pigs in both treatments were also treated with
parenteral administration of amoxicillin (15 mg/kg BW)
for 3 days by the farm staff if and when clinical signs of
systematic illness (i.e. meningitis, severe respiratory
disease, lethargy and failure to thrive and diarrhoea) or
lameness were detected in individual animals.
On farm measurements
Production data, parenteral administration of antibiotics
and mortality
Performance measurements were recorded during all the
stages. Each pen of pigs was weighed together at the end
of the first and second weaner stages and before slaugh-
ter (i.e. end of the finisher stage) and the average pig
weight was calculated. Daily feed intake of all pens was
automatically recorded by the SPOTMIX liquid feeding
system. The number of doses of parenteral injections of
AB administered to pigs in each treatment was recorded
daily by the farm staff during both the weaner and
finisher stages. Two classes of parenteral treatments
were recorded, lame and systemically ill. The proportion
of pigs injected because of systemic illness or lameness
in each treatment was calculated based on these records.
Average daily gain (ADG), average daily feed intake
(ADFI) and feed conversion ratio (FCR) were also calcu-
lated for all the stages. Number of animals that died was
recorded daily by the farm staff during both weaner and
finisher stages.
Tail lesions
A subset of 70 pigs per each weaning week (i.e. 35 per
treatment) was selected for tail lesion assessment. Tail
lesions were measured at three time points by one
trained observer. The number of pigs per pen affected by
tail lesions was recorded at the end of the first and second
weaner stages. While prior to slaughter, tails were scored
on a 5-point scale according to severity [34, 35]. The
proportion of pigs per pen affected by tail lesions was
calculated.
Slaughterhouse measurements
At the abattoir pigs were stunned with CO2 and killed
by exsanguination according to EU regulation. Enzootic
pneumonia (EP) like lesions was scored according to the
British Pig Executive (BPEX) Pig Health Scheme by one
trained observer [36]. Additionally, presence or absence
of Actinobacillus pleuropneumoniae (APP) lesions, ab-
scesses and all instances of condemnations of heart, liver
and lungs were recorded as per the decision of the act-
ing veterinary inspector. Pleurisy was scored using the
Slaughterhouse Pleurisy Evaluation System (SPES) [37]
by one trained observer on a 3-point scale where 0 = no
lesions; 1 = mild lesions, 2 = severe lesions. The propor-
tion of pigs affected by EP, APP, abscess and pleurisy was
also calculated.
Statistical analysis
Data were analysed using SAS v9.4 (SAS Inst. Inc., Cary,
NC). Alpha level for determination of significance was
0.05 and from 0.05 to 0.10 for trends. Data from the first
and second weaner stages and the finisher stage were
analysed separately to account for the change in pen
composition between stages. Pen was always considered
the experimental unit. Production data (ADG, ADFI and
FCR) were analysed using general linear models; treat-
ment was included as a fixed effect while initial mean
body weight of the pen in each stage was included in the
model as a covariate. In all stages, mortalities, injections
and slaughter data (e.g. proportion of pigs affected by
EP, APP, pleurisy and abscess) were analysed using
Chi-square test while ANOVA was used to analyse EP
and pleurisy scores between treatments. Tail lesion data
were analysed using the general linear model in which
treatment was included as a fixed effect. Results are
presented as means ± SEM. Pearson correlations were
calculated between initial body weight and mortality rate
and between initial body weight and number of injec-
tions during the entire weaner (i.e. first and second)
stage and during the finisher stage. Pearson correla-
tions were also calculated between final body weights
of weaner and finisher pigs and the corresponding
proportion of pigs affected by tail lesions. Results are
presented as the correlation coefficient (Rho) and the
corresponding P-value.
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